A new era in Alzheimer’s treatment

January 11, 2023

Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio about a timely topic in the news: The U.S. Food and Drug Administration on Friday, Jan. 6, 2023, approved lecanemab, a drug that targets the basic pathophysiology of Alzheimer’s disease. The FDA action is an “accelerated approval” of the […]


Inflammatory trigger a new clue in Alzheimer’s

January 6, 2023

Researchers discover toxic process involving ‘jumping genes’ Scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) today reported that an inflammatory trigger like one present during viral infections is elevated in Alzheimer’s disease and progressive supranuclear palsy, a rare brain disorder. “We have identified a new trigger of […]





New hope for treating the toughest cancers

December 20, 2022

The Mays Cancer Center at UT Health San Antonio — South Texas’ only National Cancer Institute-Designated Cancer Center — is putting a decades-old antidepressant drug to new use treating breast cancers that don’t respond to existing therapies. Research in the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio provided […]

Ratna Vadlamudi, PhD, lab group


Barshop Institute’s Palavicini attracts early scientist award

December 15, 2022

American Federation for Aging Research grant allows exploration of signaling molecules toxic in Alzheimer’s, diabetes, aging The American Federation for Aging Research (AFAR) selected Juan Pablo Palavicini, PhD, an early career scientist at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), to receive the 2022 Glenn Foundation for Medical […]